A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
ATTAIN-CN
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once- Daily Oral Orforglipron Compared With Placebo in Chinese Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
2 other identifiers
interventional
192
1 country
13
Brief Summary
The purpose of this study is to learn how well orforglipron works and how safe it is in Chinese adults with obesity or overweight and related health problems. Participation in this study will last about 53 weeks (about 1 year).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3 obesity
Started Dec 2026
Shorter than P25 for phase_3 obesity
13 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 25, 2026
CompletedFirst Posted
Study publicly available on registry
August 27, 2026
CompletedStudy Start
First participant enrolled
December 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2028
Study Completion
Last participant's last visit for all outcomes
March 1, 2028
August 27, 2026
August 1, 2026
1.2 years
August 25, 2026
August 25, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Mean Percent Change From Baseline in Body Weight
Baseline, Week 48
Secondary Outcomes (10)
Mean Change from Baseline in Waist Circumference
Baseline, Week 48
Mean Change from Baseline in Body Mass Index (BMI)
Baseline, Week 48
Mean Change from Baseline in Hemoglobin A1c (HbA1c)
Baseline, Week 48
Mean Change from Baseline in Fasting Glucose
Baseline, Week 48
Mean Percent Change from Baseline in Fasting Insulin
Baseline, Week 48
- +5 more secondary outcomes
Study Arms (2)
Orforglipron
EXPERIMENTALParticipants will receive orforglipron orally.
Placebo
PLACEBO COMPARATORParticipants will receive placebo orally.
Interventions
Eligibility Criteria
You may qualify if:
- Have body mass index (BMI) ≥28.0 kilograms per square meter (kg/m2) and \<30 kg/m2 or ≥24.0 kg/m2 and \<28 kg/m2, and at least 1 of the following weight-related comorbidities at screening:
- hypertension
- dyslipidemia
- obstructive sleep apnea
- Fatty liver
- cardiovascular disease
- Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight
You may not qualify if:
- Have type 1 diabetes (T1D), type 2 diabetes (T2D), or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
- Have a self-reported change in body weight \>5 kg within 90 days prior to screening
- Had chronic or acute pancreatitis any time prior to screening
- Have family (first-degree relative) or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) syndrome
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (13)
Sichuan Provincial People's Hospital
Chengdu, 610072, China
Zhujiang Hospital
Guangzhou, 510280, China
The first Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, 310003, China
Zhejiang Provincial People's Hospital
Hangzhou, 310014, China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, 150001, China
The Second People's Hospital of Hefei
Hefei, 230011, China
Jinan Central Hospital
Jinan, 250013, China
The First Affiliated Hospital of Henan University of Science &Technology
Luoyang Shi, 471003, China
Jiangxi Provincial People's Hospital
Nanchang, 330006, China
Nanjing First Hospital
Nanjing, 210006, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, 210011, China
Jiangsu Province Hospital
Nanjing, 210029, China
Shanghai Sixth People's Hospital
Shanghai, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Central Study Contacts
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Physicians interested in becoming principal investigators please contact
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 25, 2026
First Posted
August 27, 2026
Study Start (Estimated)
December 1, 2026
Primary Completion (Estimated)
March 1, 2028
Study Completion (Estimated)
March 1, 2028
Last Updated
August 27, 2026
Record last verified: 2026-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR
- Time Frame
- Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
- Access Criteria
- A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.